The impact of risk-reducing hysterectomy and bilateral salpingo- oophorectomy on survival in patients with a history of breast cancer - A population-based data linkage study

International Journal of Cancer

Volumn 134, Issue 9, 2014, Pages 2211-2222

  Obermair, Andreas ^a   Youlden, Danny R ^b   Baade, Peter D ^b,c   Janda, Monika ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b CANCER COUNCIL QUEENSLAND   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

breast cancer; ovarian cancer; prophylactic surgery; survival; uterine cancer

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; BILATERAL SALPINGOOOPHORECTOMY; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SALPINGOOOPHORECTOMY; SURGICAL RISK; YOUNG ADULT;

BREAST CANCER; OVARIAN CANCER; PROPHYLACTIC SURGERY; SURVIVAL; UTERINE CANCER;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SALPINGECTOMY; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84896718337     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28537     Document Type: Article

References (43)

1. Cancer IAfRi. Globocan cancer fact sheet: breast cancer, vol. 2013. Available at: http://globocan.iarc.fr/factsheets/cancers/breast.asp, 2008. Accessed on September 20, 2013.
2. Shin HR, Boniol M, Joubert C, et al. Secular trends in breast cancer mortality in five East Asian populations: Hong Kong, Japan, Korea, Singapore and Taiwan. Cancer Sci 2010; 101: 1241-6.
3. Shin HR, Joubert C, Boniol M, et al. Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control 2010; 21: 1777-85.
4. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
5. Youlden DR, Cramb SM, Dunn NA, et al. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012; 36: 237-48.
6. Johnson RH, Chien FL, Bleyer A,. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 2013; 309: 800-5.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360: 187-95.
8. Calle EE, Kaaks R,. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-91.
9. Youlden DR, Baade PD,. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 2011; 11: 83.
10. Kramer JL, Velazquez IA, Chen BE, et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005; 23: 8629-35.
11. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-75.
12. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-15.
13. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-22.
14. Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999; 8: 741-7.
15. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-89.
16. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30.
17. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006; 24: 863-71.
18. Narod SA,. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010; 7: 702-7.
19. Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010; 119: 7-17.
20. Jacoby VL, Grady D, Wactawski-Wende J, et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med 2011; 171: 760-8.
21. Parker WH,. Bilateral oophorectomy versus ovarian conservation: effects on long-term women's health. J Minimally Invasive Gynecol 2010; 17: 161-6.
22. Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009; 113: 1027-37.
23. Parker WH, Broder MS, Liu Z, et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005; 106: 219-26.
24. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16: 15-23.
25. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology 2009; 33: 32-40.
26. Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006; 7: 821-8.
27. Shuster LT, Gostout BS, Grossardt BR, et al. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 2008; 14: 111-16.
28. Whittemore AS, Harris R, Itnyre J,. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1212-20.
29. Press DJ, Sullivan-Halley J, Ursin G, et al. Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women's contraceptive and reproductive experiences study. Am J Epidemiol 2011; 173: 38-47.
30. Lambert P, Royston P,. Further development of flexible parametric models for survival analysis. Stata J 2009; 9: 265-90.
31. Royston P, Lambert P,. Flexible parametric survival analysis using Stata: beyond the Cox model. Stata Press, 2011.
32. Austin PC,. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
33. Brewster AM, Bedrosian I, Parker PA, et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 2012; 118: 5637-43.
34. Austin PC,. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008; 27: 2037-49.
35. Prowell TM, Davidson NE,. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 2004; 9: 507-17.
36. Swain SM, Jeong JH, Geyer CE, Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-65.
37. Bines J, Oleske DM, Cobleigh MA,. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-29.
38. Reichman BS, Green KB,. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst Monogr 1994; 16: 125-9.
39. Zickl L, Francis P, Fleming G, et al.; International Breast Cancer Study Group aNABCG. SOFT and TEXT: trials of tamoxifen and exemestane with and without ovarian function suppression for premenopausal women with hormone receptor-positive early breast cancer. Cancer Res 2012; 72 (Suppl 3).
40. Fong A, Shafiq J, Saunders C, et al. A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of «optimal» therapy. Breast 2012; 21: 562-9.
41. Bell RJ, Schwarz M, Fradkin P, et al. Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. Menopause 2013; 20: 721-6.
42. Parker WH, Feskanich D, Broder MS, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses' Health Study. Obstet Gynecol 2013; 121: 709-16.
43. Parker WH, Shoupe D, Broder MS, et al. Elective oophorectomy in the gynecological patient: when is it desirable? Curr Opin Obstet Gynecol 2007; 19: 350-4.